Abstract
An assessment of genetic factors influence on ibandronic acid effect in postmenopausal osteoporosis treatment can significantly bring us closer to the practical use of this results in prognostic genetics and personalized medicine. The aim was the study of associations between 283 A>G (BsmI, rs1544410) polymorphisms of vitamin D receptor gene (VDR) and ibandronic acid efficacy in postmenopausal osteoporosis treatment.
 117 women with postmenopausal osteoporosis were examined through treatment dynamics. A 12-month therapy course included the use of ibandronic acid according to standard regimen. Evaluation of treatment effectiveness was carried out by changes (%) in bone mineral density (BMD) separately for each area by dual- energy X-ray absorptiometry. Real-time PCR was used to determine VDR gene rs1544410 polymorphism.
 It was found that for 12 months ibandronate use caused significant (p<0.001) BMD increase. BMD increase ranged from 2.71±0.53% in left femoral neck zone to 4.63±0.53% in the L1-L4 lumbar vertebrae. The treatment outcome did not depend (p>0.05) on age, height, weight, body mass index, and postmenopause duration. GG genotype of rs1544410 polymorphism was associated with lower BMD growth rate in L1-L4 lumbar vertebrae (p=0.036).
 Screening of women with postmenopausal osteoporosis for polymorphic variants of VDR gene (rs1544410) before antiresorptive therapy with ibandronic acid may be appropriate to predict the effect and individualize treatment and prophylactic measures. The obtained results can contribute to more complete understanding of osteoporosis pharmacogenetics
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
